期刊
JOURNAL OF NUCLEAR MEDICINE
卷 62, 期 3, 页码 354-359出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.120.248120
关键词
urokinase-type plasminogen activator receptor; prostate cancer; PET/MRI; risk stratification; active surveillance; Gleason score
资金
- European Union [670261, 668532]
- Lundbeck Foundation
- Novo Nordisk Foundation
- Innovation Fund Denmark
- Danish Cancer Society
- Arvid Nilsson Foundation
- Svend Andersen Foundation
- Neye Foundation
- Research Foundation of Rigshospitalet
- Danish National Research Foundation [126]
- Research Council of the Capital Region of Denmark
- Danish Health Authority
- John and Birthe Meyer Foundation
- Research Council for Independent Research
The study aimed to evaluate the correlation between uptake of the PET ligand Ga-68-NOTA-AE105 and Gleason score in patients undergoing prostate biopsy. Results showed a significant positive correlation between SUVmax and Gleason score. SUVmax could discriminate between low-risk Gleason score profiles and intermediate risk Gleason score profiles accurately.
The aim of this study was to evaluate the correlation between uptake of the PET ligand Ga-68-NOTA-AE105, targeting the urokinase-type plasminogen activator receptor (uPAR), and Gleason score in patients undergoing prostate biopsy. Methods: Patients with clinical suspicion of prostate cancer (PCa) or previously diagnosed with PCa were prospectively enrolled in this phase 2 trial. A combination of uPAR PET and multiparametric MRI (mpMRI) was performed, and the SUV in the primary tumor, as delineated by mpMRI, was measured by 2 independent readers. The correlation between the SUV and the Gleason score obtained by biopsy was assessed. Results: A total of 27 patients had histologically verified PCa visible on mpMRI and constituted the study population. There was a positive correlation between the SUVmax and the Gleason score (Spearman rho = 0.55; P = 0.003). Receiver operating characteristic analysis showed an area under the curve of 0.88 (95% CI, 0.67-1.00) for discriminating a Gleason score of greater than or equal to 3 + 4 from a Gleason score of less than or equal to 3 + 3. A cutoff for the tumor SUVmax could be established with a sensitivity of 96% (79%-99%) and a specificity of 75% (30%-95%) for detecting a Gleason score of greater than or equal to 3 + 4. For discriminating a Gleason score of greater than or equal to 4 + 3 from a Gleason score of less than or equal to 3 + 4, a cutoff could be established for detecting a Gleason score of greater than or equal to 4 + 3 with a sensitivity of 93% (69%-99%) and a specificity of 62% (36%-82%). Conclusion: SUV measurements from uPAR PET in primary tumors, as delineated by mpMRI, showed a significant correlation with the Gleason score, and the tumor SUVmax was able to discriminate between low-risk Gleason score profiles and intermediate risk Gleason score profiles with a high diagnostic accuracy. Consequently, uPAR PET/MRI could be a promising method for the noninvasive evaluation of PCa and might reduce the need for repeated biopsies (e.g., in active surveillance).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据